Yes your correct HB it was clearly a cut he comes back in and says on top of that, after stating that we will have protection for using this in a clinical setting for a long time. So not sure what he was talking about there but obviously crossed a line on information release prior to market release.
My gem take away was where he was answering a question about working with IMU and after thanking LC and PH he goes on to thank the trial team the ones who put the trials together but also the one's who now are making sure "we have a very robust supply of virus we are expecting that we are going to go on with the trials to see positive results and keep going to approval" that sentence says a lot to me. I did mention it in another thread but when you put that with his referrals to patent protection and great results it looks pretty good, unlike the SP.
The SP doesn't but that's due to lots of factors main one being finance, no evidence of anything else untoward except fear and panic manipulation and human nature to follow the crowd, once finance is sorted and we get an update on trials I am sure IMU will be rerated and quickly.
Good luck to all
IMU Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)